초록/요약

Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been recommended for adults aged >= 65 years. To evaluate functional immune response against the additional 11 serotypes that are included in PPSV23, but not the 13-valent pneumococcal conjugate vaccine (PCV13), serotype-specific anti-pneumococcal antibodies were examined using an opsonophagocytic assay (OPA). Methods: Participants >= 65 years of age that were naive to the pneumococcal vaccine were enrolled. They were divided into two groups according to their age: group 1 (N = 30; aged 65-74 years) and group 2 (N = 32; aged >= 75 years). The functional antibody response prior to and 4 weeks post -immunization with PPSV23 was determined, using a multiplexed OPA (MOPA) for 11 pneumococcal serotypes (2, 8, 9N, 10A, VIA, 12F, 15B, 17F, 20B, 22F, and 33F). Results: Geometric mean OPA titers (GMTs) to 11 serotypes were significantly increased in both groups post -immunization compared to those prior to immunization. The GMTs for all serotypes were not significantly different between the two groups after immunization. The proportion of subjects with OPA titers post -immunization of >= 8 and >= 64 was 93-100% and 80-100% for the 11 serotypes, respectively, while subjects with a >= 4-fold increase in OPA titers ranged from 9 to 90% for the 11 serotypes. Conclusions: This study revealed that PPSV23 vaccination induced significant functional immune responses to 11 non-PCV13 serotypes in older adults. The MOPA has been shown to be a useful tool for future application in evaluating new PCVs in older adults. (C) 2017 The Author(s). Published by Elsevier Ltd.